Skip to main content

$0.125 (0.00%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
20 May 2025 at 7:17am
Register to track EMD and receive email alerts.

Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD

StockBot

416,823 posts

EMD released this announcement to the ASX on 20 January 2022, 9:41. The announcement is marked as price sensitive, and is 4 page(s) in length and 269.86kb in size.

You can view all announcements from EMD and see how they appear on a price chart on the announcements page.

At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).

Other Recent Announcements from EMD
Trading Halt 29 June 2023, 9:33
Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 June 2023, 9:10
Section 708A(5)(e) Notice 10 May 2023, 18:37
Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD 20 January 2022, 9:41
Notification regarding unquoted securities - EMD 31 December 2021, 15:03
Proposed issue of securities - EMD 30 December 2021, 10:15
Emyria appoints Sixty Two Capital as corporate advisor 30 December 2021, 9:57
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EMD and receive email alerts.